findmyKOL
Clinical trialNCT02159755Active, not recruitingPhase 1Interventional

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment28Recurrent Mantle Cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Washington University School of Medicine

    St Louis, Missouri, United States

  • Nyp/weill Cornell Medical Center

    New York, New York, United States

  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Aug 2014
Primary completion
25 Jun 2018
Completion
30 Apr 2027
Last update posted
27 May 2026
Registered enrollment
28
Registry id
NCT02159755

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.